Cargando…
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
BACKGROUND: Tuberous sclerosis (TSC) is a hamartoma syndrome in which renal and lung tumors cause the greatest morbidity. Loss of either TSC1 or TSC2 in TSC hamartomas leads to activation of mTORC1 and suppression of AKT. Recent studies indicate that inhibition of mTORC1 with RAD001 (everolimus) lea...
Autores principales: | Pollizzi, Kristen, Malinowska-Kolodziej, Izabela, Stumm, Michael, Lane, Heidi, Kwiatkowski, David |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702302/ https://www.ncbi.nlm.nih.gov/pubmed/19527517 http://dx.doi.org/10.1186/1476-4598-8-38 |
Ejemplares similares
-
Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
por: Benavides-Serrato, Angelica, et al.
Publicado: (2017) -
The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling
por: Delgoffe, Greg M., et al.
Publicado: (2011) -
Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
por: Benavides-Serrato, Angelica, et al.
Publicado: (2019) -
Retraction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
Publicado: (2023) -
mTORC2: The other mTOR in autophagy regulation
por: Ballesteros‐Álvarez, Josué, et al.
Publicado: (2021)